Dermata Therapeutics develops and commercializes over-the-counter and cosmetic skincare products using Bioneedle, a proprietary powder derived from freshwater sponge that exfoliates skin and stimulates collagen production. The company sells through direct-to-consumer e-commerce and business-to-business channels targeting aestheticians and dermatologists, offering product lines for acne, general skin renewal, and other common skin conditions. Revenue comes from premium-priced subscriptions and one-time purchases via its Tome Skincare brand, supported by digital marketing and professional endorsements, while the company outsources manufacturing to third-party partners and holds patents protecting its formulations and delivery systems.